32,532 28,480 31,879 26,175
Alexza Pharmaceuticals, Inc.
(a development stage enterprise)
Condensed Consolidated Balance Sheets
(in thousands)
June 30, December 31,
2008 2007
Unaudited (1)
Assets
Cash, cash equivalents and marketable
securities $64,005 $69,391
Investments held by Symphony Allegro, Inc. 31,310 39,449
Other current assets 996 13,432
Total current assets 96,311 122,272
Property and equipment, net 25,302 26,156
Other non-current assets 666 697
Total assets $122,279 $149,125
Liabilities, noncontrolling interest
and stockholders' equity
Current liabilities $16,453 $16,180
Non-current liabilities 30,826 33,002
Noncontrolling interest in Symphony
Allegro, Inc. 14,304 23,952
Stockholders equity 60,696 75,991
Total liabilities, non controlling
interest and stockholders' equity $122,279 $149,125
(1) Derived from audited consolidated financial statements at that date.
'/>"/>SOURCE Alexza Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related medicine technology :1.
Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients2.
Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status3.
Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache4.
Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status5.
Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)6.
Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients7.
Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting8.
Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder9.
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation10.
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting11.
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)